Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta-analysis

Review of 25 studies (n=330,780) found ACEi use reduced pneumonia risk by 26% in non-COVID-19 patients (p<0.001), but ARBs did not reduce risk. Also ACEi use reduced the risk of COVID-19 (OR0.87, p=0.014), but ARBs did not reduce COVID-19 risk.

Source:

British Journal of Clinical Pharmacology